Microbicides for Prevention Research
Overview
The HPTN's microbicide agenda is
transitioning to the
Microbicide Trials
Network (MTN). Information on current HPTN microbicide trials
will be maintained on the HPTN website until this transition process is
complete.
Microbicides are antimicrobial products
formulated for application to the surface of the vagina and/or rectum for
the prevention of HIV transmission during sexual intercourse. They are
considered to be one of the most promising preventive interventions to
emerge over the past decade.
There are several mechanisms of action that
may allow microbicides to prevent HIV transmission. These are:
- killing or inactivating pathogens
- strengthening the body's normal defenses
- blocking infection by creating a barrier
between the pathogen and target cells
- preventing infection from spreading to
other cells
More than 60 products have been evaluated
as potential microbicide candidates. The majority of these products have
undergone preclinical evaluation, some have advanced into human studies.
To be successful in reducing HIV transmission the ideal topical
microbicide must have several characteristics:
- it must be safe and effective
- inexpensive and widely accepted
- available in both spermicidal and
non-spermicidal formulations
- able to be used without partner
knowledge.
Even a partially effective microbicide
might have a profound impact on the dynamics of HIV transmission. In fact,
researchers have developed a mathematical model that shows that if even a
small proportion of women in lower income countries using a 60%
efficacious microbicide in half the sexual encounters where condoms are
not used, could avert 2.5 million HIV infections over 3 years.
|
|
HIVNET 016A |
Condom Promotion and Counseling Study |
(Concluded) |
|
HPTN 032 |
Male Tolerance Study of BufferGel and PRO 2000/5 Gel (P) |
(Concluded) |
|
HPTN 035 |
Phase II/IIb Safety and Effectiveness Study of the Vaginal Microbicides BufferGel and 0.5% PRO2000/5 Gel (P) for the Prevention of HIV Infection in Women |
(Closed to Accrual) |
|
HPTN 047 |
A Phase I Safety and Acceptability Study of the Investigational Vaginal Microbicide PRO 2000/5 Gel (P) |
(Concluded) |
|
HPTN 049 |
Phase I Safety and Acceptability Study of the Vaginal Microbicide 6% Cellulose Sulfate Gel Among HIV-Infected Women |
(Concluded) |
|
HPTN 050 |
Phase I Safety and Acceptability Study of the Vaginal Microbicide Agent PMPA Gel |
(Concluded) |
|
HPTN 055 |
HIV Prevention Preparedness Study |
(Concluded) |
|
HPTN 056 |
Characterization of Baseline Mucosal Indices of Injury and Inflammation in Men for Use in Rectal Microbicide Trials |
(Participants Off Study & Primary Analysis Complete) |
|
HPTN 059 |
Phase II Expanded Safety and Acceptability Study of the Vaginal Microbicide 1% Tenofovir Gel |
(Closed to Follow Up) |
|
